Genzyme

First MS patients in the U.S. receive Genzyme’s Lemtrada following FDA approval

Thursday, December 4, 2014 01:43 PM

Genzyme, a Sanofi company, has announced that the first U.S. patients have initiated treatment with Lemtrada (alemtuzumab) in the commercial setting following its Nov. 14 FDA approval for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

More... »


Sanofi board ousts CEO Viehbacher

Thursday, October 30, 2014 08:46 AM

Paris-based biopharmaceutical company Sanofi ousted CEO Chris Viehbacher Wednesday, just two days after reporting disappointing quarterly earnings.

More... »


Fidelity Biosciences and Atlas Venture launch Unum Therapeutics

Wednesday, October 22, 2014 11:28 AM

Fidelity Biosciences and Atlas Venture, with participation from Sanofi-Genzyme BioVentures, have launched Unum Therapeutics, a company developing cellular immunotherapy to treat cancer. Fidelity Biosciences invests venture capital in biopharmaceutical, medical technology, healthcare information technology and healthcare service companies, while Atlas Venture is an early-stage investor. All three are based in Cambridge, Mass.

More... »

FDA expands approval of Lumizyme to treat Pompe disease

Monday, August 4, 2014 03:27 PM

The FDA has approved Lumizyme (alglucosidase alfa) for treatment of patients with infantile-onset Pompe disease, including patients who are less than eight years of age. In addition, the risk evaluation and mitigation strategy (REMS) known as the Lumizyme ACE (Alglucosidase Alfa Control and Education) Program is being eliminated.

More... »

Jon L. Hart named CEO of med fusion

Friday, April 11, 2014 01:23 PM

med fusion, an integrated, advanced laboratory and clinical trials service organization, has appointed Jon L. Hart CEO, effective March 31. This appointment is the next step in the organization’s continued drive towards becoming the clear leader in providing lab and clinical trial support to healthcare providers and biotech/pharmaceutical companies through a patient-centric support model.

More... »

Minerva Neurosciences expands executive team

Thursday, March 6, 2014 10:30 AM

Minerva Neurosciences, a developer of new therapies to treat neuropsychiatric diseases and disorders, has launched the new company web site (www.minervaneurosciences.com) following the successful transfer of the Minerva Neurosciences corporate headquarters from New Jersey to Cambridge, Mass. The establishment of a new corporate headquarters follows the recent appointment of Rogerio Vivaldi, M.D., MBA, as the new president and CEO, and Marc Beer as the new chairman of the board of directors of Minerva Neurosciences. The company was founded in 2013 by the merger of Cyrenaic Pharmaceuticals and Sonkei Pharmaceuticals.

More... »

Fidelity Biosciences, Regenx Biosciences launch Dimension Therapeutics

Friday, November 1, 2013 11:10 AM

Fidelity Biosciences and Regenx Biosciences have formed Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases. Dimension will focus on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia and building out a product engine for AAV therapeutics.

More... »

PhRMA to open Middle East and Africa regional office at DuBiotech, UAE

Wednesday, October 9, 2013 02:09 PM

Pharmaceutical Research and Manufacturers of America (PhRMA) plans to establish its Middle East and Africa regional office within Dubai Biotechnology and Research Park (DuBiotech), a free zone dedicated to facilitating and fostering the growth of the life sciences industry in the UAE and a member of Tecom Investments, a developer and operator of business parks.

More... »

Third Rock Ventures expands, strengthens team

Wednesday, May 15, 2013 09:38 AM

Third Rock Ventures, a venture capital firm focused on building healthcare companies, has expanded and strengthened its team with several appointments and role changes. These additions allow Third Rock to continue to support the launch of new companies focused on disruptive areas of science and medicine, the maturation and development of its current portfolio companies and the overall strategy and direction of the firm.

More... »

Sanofi, Transgene form long-term collaboration for production of immunotherapy treatments

Monday, March 25, 2013 12:24 PM

Global healthcare company Sanofi and biopharmaceutical company Transgene have signed a collaboration agreement for the creation of a new state-of-the-art industrial platform dedicated to the production of immunotherapy products including Transgene's therapeutic products.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs